Drugs / 6-mercaptopurine (6-MP)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00136435 Background | Jun 2002 → Nov 2008 | acute lymphoblastic leukemia | Dana-Farber Cancer Institute | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 6-mercaptopurine (6-MP) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00136435 ↗ |
| Route | Oral | “CNS Therapy: Taken orally on days 1-14.” NCT00136435 ↗ |